Use of nateglinide as a hypoglycemic agent for treating impaired glucose metabolism

摘要

Nateglinide can be used in the manufacture of a medicament for subjects with IGM for the prevention or delay of progression to overt diabetes mellitus type 2, the prevention, reduction or delay in onset of a condition selected from the group consisting of increased microvascular complications, increased cardiovascular morbidity, excess cerebrovascular diseases; increased cardiovascular mortality and sudden death; and other metabolic disturbances that are associated with IGM. Preferably the medicament comprises a dosage of 30mg or 60mg of nateglinide.